A double-blind trial of the H2 receptor antagonist cimetidine, and the H1 receptor antagonist promethazine hydrochloride in the treatment of atopic dermatitis.
Twenty young adults with atopic dermatitis were allocated randomly in a clinical trial to compare the action of the H2 receptor antagonist cimetidine (Tagamet) and the H1 receptor antagonist promethazine hydrochloride (Phenergan), singly and in combination. No significant differences were found, clinically or in the laboratory investigations, between the patients on either drug alone or the combination of the two.
D000293:Adolescent; D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011398:Promethazine / Q000627:therapeutic use*; D011897:Random Allocation
D006146:Guanidines; D002927:Cimetidine; D011398:Promethazine